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In the September 2002 issue of the Journal, in the article
entitled, “BRCA2 T2722R Is a Deleterious Allele That
Causes Exon Skipping,” by Fackenthal et al. (71:625–
631), the authors reported evidence for a BRCA2 exon-
skipping allele carrying a disruption in a potential exonic
splicing enhancer (ESE). The evidence for the BRCA2
T2722R allele being deleterious per se was its cosegrega-
tion with affected members of a family exhibiting classic
hereditary breast cancer phenotypes, including high-fre-
quency breast cancer occurrence among first-degree rela-
tives, early-onset breast cancer, bilateral breast cancer, and
ovarian cancer. Using methods published elsewhere, we
predicted that the base change in this allele, 8393CrG,
disrupts three overlapping consensus ESE sequences, po-
tentially resulting in skipping exon 18 during splicing.
We performed RT-PCR on mononuclear blood cells from
an affected mutation carrier and on control lymphoblasts
from an unaffected individual, and we found that the
exon skipping in the mutation carrier was far more pro-
nounced than the background level seen in the wild type
BRCA2 (fig. 3). However, as discussed on p. 627, this
result was from a potentially saturating end-point PCR
(made necessary by limited patient material) and was not
fully quantitative.
Since making these observations, we and others have
sequenced the full-length RT-PCR product and have
found that, on several occasions, both the mutant and
wild-type alleles are detectable. Thus, the putative
T2722R-specific exon-skipping event is not complete.
The possibility of both mutant and wild-type alleles con-
tributing to correctly spliced messages was discussed on
page 629. As this new evidence suggests that exon-skip-
ping may not be fully penetrant in blood cells, the au-
thors feel it is important to regard the BRCA2 T2722R
allele as an unclassified variant until further analysis can
provide definitive evidence of clinically deleterious beha-
vior in breast epithelial cells.
